First Wave BioPharma, Inc. — Q1 2024 Form 10-Q
Filing identity: The supplied filing is for First Wave BioPharma, Inc. (Nasdaq: FWBI), not Gridai Technologies Corp. It covers the three months ended March 31, 2024; financial statements are unaudited.
Business context and reporting period
First Wave is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases. Its pipeline includes Latiglutenase, Adrulipase, Capeserod and Niclosamide. In March 2024, it acquired ImmunogenX, adding Latiglutenase and the CypCel celiac-disease marker program. The company reported no revenue to date.
Financial results and liquidity
- Revenue: None reported; the company states it has not generated revenue.
- Net result: Net income of $5.57 million, versus a $4.07 million net loss in Q1 2023. The 2024 income includes a $14.86 million income tax benefit from releasing part of a deferred-tax valuation allowance following the acquisition; it does not indicate operating profitability. Loss before tax was $9.29 million.
- Operating expenses: $9.23 million, up $5.16 million from $4.06 million. Research and development was $0.57 million, down 58%; general and administrative expense was $8.66 million, up 220%. The company attributed much of the G&A increase to approximately $4.0 million of noncash acquisition-advisor fees.
- Cash flow: Operating cash use was $3.75 million, compared with $2.85 million in Q1 2023. Financing provided $3.38 million, primarily from the March registered offering; cash, cash equivalents and restricted cash decreased $0.28 million.
- Cash and working capital: At March 31, cash and cash equivalents were $3.43 million and working capital was approximately $1.3 million. Management expected cash on hand to fund planned operations into June 2024.
- Debt and obligations: Balance-sheet debt was $6.78 million, including $6.40 million long-term and $0.39 million current. Principal debt was $7.25 million before a $0.46 million debt discount; the acquired revolving facility had $5.36 million outstanding, no remaining availability, and $1.33 million accrued interest. Total liabilities were $13.27 million.
- Margins: Not meaningful because the company reported no revenue.
- Acquisition-related assets: The IMGX acquisition added $63.0 million of in-process R&D and $18.35 million of goodwill. Total assets were $91.13 million, compared with $6.88 million at year-end 2023.
Material changes versus the prior comparable period
- The IMGX acquisition materially expanded the pipeline and balance sheet and added debt, preferred stock and acquisition-related assets. The preliminary purchase consideration was approximately $60.1 million, principally Series G preferred stock.
- Operating expenses rose despite lower R&D spending, chiefly because of transaction-related and advisory costs and higher legal and consultant expenses. Management expected R&D expense to increase as work on Latiglutenase began and G&A expense to decrease during the rest of 2024.
- The reported swing to net income from a loss was driven by the discrete tax benefit, while operating loss increased to $9.23 million from $4.06 million.
Outlook, risks and unusual items
- Going concern: The filing states that recurring losses and negative operating cash flows, limited cash runway and dependence on additional financing raise substantial doubt about the company’s ability to continue as a going concern for one year after issuance. It expects to need additional equity and/or debt funding.
- Subsequent financing: A May 2024 registered direct offering generated approximately $1.1 million gross proceeds before expenses, with warrants also issued. This followed the March offering, which generated approximately $4.0 million gross and $3.6 million net proceeds.
- Nasdaq: The company reported regaining compliance with the minimum bid-price and minimum stockholders’ equity rules and receiving a Letter of Reprimand over a prior shareholder-approval rule violation. Nasdaq separately determined that the IMGX acquisition constituted a change of control and required the company to satisfy initial-listing criteria before Series G conversion approval or other triggering changes. Continued listing is not assured.
- Potential dilution and preferred-stock terms: Series G preferred stock is convertible, subject to stockholder approval, into 12.37 million common shares and may become redeemable at the holder’s option after six months at a price tied to the common stock’s closing price. The filing lists approximately 15.40 million potential common shares issuable from outstanding securities at March 31.
- Other risks: Clinical and regulatory uncertainty, dependence on third-party manufacturers and research providers, intellectual-property protection, capital access, and market and geopolitical uncertainty. The filing also describes a non-binding term sheet to sell Niclosamide, expected to close in the first half of 2024; the supplied text does not confirm completion.
- Other pipeline economics: Under the Capeserod license, Sanofi may receive up to $46 million in development and regulatory milestones, up to $235 million in commercial milestones, and royalties.
Important facts for investors to verify
- Confirm the issuer identity: this is a First Wave BioPharma filing, despite the request metadata naming Gridai Technologies Corp.
- Review cash use, financing availability and subsequent cash balances against the stated June 2024 runway and going-concern warning.
- Verify the status and terms of any further financing, including warrant dilution and registration obligations from the May offering.
- Track Nasdaq’s initial-listing requirements and the approvals and potential redemption implications for Series G preferred stock.
- Assess the IMGX purchase-price allocation and the development and impairment risks associated with the $63.0 million IPR&D asset and goodwill.
- Confirm whether the proposed Niclosamide transaction closed and review the clinical, regulatory and funding milestones for the remaining pipeline.